Climb Bio Inc
CLYMLatest QuantConomy context for CLYM: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
Climb Bio Inc
QuantConomy has a structured record for CLYM. More descriptive asset metadata will appear here when the platform record includes it.
- Symbol
- CLYM
- Name
- Climb Bio Inc
- Coverage
- 3 market/data records
- Sources
- alpaca fmp alphavantage sec nasdaq
Recent signals for CLYM
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| passive large holder | neutral | 40 | Jul 8, 02:15 AM | RA Capital Management, L.P. decreased passive stake in CLYM from 33.00% to 33.00% - (13G - passive investment) - 23,249,186 shares - [weak neutral signal] |
| earnings release | neutral | 40 | Mar 5, 12:00 AM | CLYM filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-03-05. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read). |
| material agreement | bullish | 85 | Jun 12, 08:50 PM | CLYM filed 8-K: Material Definitive Agreement, Other Events - 2 material events - [very strong bullish signal] |
EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).
OWNERSHIP signals are experimental: historical 13D/G coverage is still being backfilled, so results may be sparse or empty.
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| CLYM | NASDAQ | alpaca | Climb Bio, Inc. Common Stock |
| CLYM | NASDAQ | fmp | Climb Bio, Inc. |
| CLYM | NASDAQ | alphavantage | Eliem Therapeutics Inc |
Recent insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 27, 2026 | Brennan Aoife | President and CEO | exercise | 68,750 | — | — | 4 on EDGAR |
| Jun 5, 2026 | WILLIAMS DOUGLAS E | Director | grant | 40,000 | — | — | 4 on EDGAR |
| Jun 5, 2026 | Cumbo Alexander | Director | grant | 40,000 | — | — | 4 on EDGAR |
| Jun 5, 2026 | Levin Andrew David | Director | grant | 40,000 | — | — | 4 on EDGAR |
| Jun 5, 2026 | Dunn Judith | Director | grant | 40,000 | — | — | 4 on EDGAR |
| Jun 5, 2026 | Thomas Stephen Basil | Director | grant | 40,000 | — | — | 4 on EDGAR |
| Jun 5, 2026 | Drapkin Kimberlee C | Director | grant | 40,000 | — | — | 4 on EDGAR |
| Jun 5, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | grant | 40,000 | — | — | 4 on EDGAR |
| Apr 29, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | grant | 2,106,000 | $9.50 | $20,006,789 | 4 on EDGAR |
| Feb 25, 2026 | Thomas Stephen Basil | Director | sale | 33,687 | $7.00 | $235,964 | 4 on EDGAR |
| Feb 12, 2026 | Thomas Stephen Basil | Director | sale | 90,000 | $5.23 | $470,988 | 4 on EDGAR |
| Jan 6, 2026 | ALTSCHULLER Susan | Chief Financial Officer | grant | 142,500 | — | — | 4 on EDGAR |
| Jan 6, 2026 | Wilson Perrin Megan | Chief Business Officer | grant | 300,000 | — | — | 4 on EDGAR |
| Jan 6, 2026 | Driscoll Cindy | Senior Vice President, Finance | grant | 100,000 | — | — | 4 on EDGAR |
| Jan 6, 2026 | Brennan Aoife | President and CEO | grant | 700,000 | — | — | 4 on EDGAR |
| Jan 5, 2026 | RA CAPITAL MANAGEMENT, L.P. | Insider | purchase | 7,111 | $3.50 | $24,889 | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Query CLYM context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access